AB-201
- Generic Name
- AB-201
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
AB-201 is a CAR-NK cell therapy targeted against HER2. It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.
- Associated Conditions
- -
- Associated Therapies
- -
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT06341647
- Locations
- 🇦🇺
The Alfred Hosptial, Melbourne, Victoria, Australia
🇦🇺Austin Hosptial, Melbourne, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT05678205
- Locations
- 🇺🇸
Oregon Health Science University (OHSU), Portland, Oregon, United States
🇰🇷The Catholic University of Korea, St. Vincent's Hospital, Suwon, Gyeonggi-do, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath